top of page
Browse by category
Search
SURMOUNT-5: Zepbound superior to Wegovy in head-to-head trial showing an average weight loss of 20.2% vs. 13.7%
Eli Lilly and Company has announced topline results from the SURMOUNT-5 phase 3b open-label randomised clinical trial that found Zepbound...
SURMOUNT-5: Tirzepatide and semaglutide go head-to-head in battle of weight loss drugs
Eli Lilly and Company has registered its intent to carry out a Phase 3b clinical trial that will see the company’s tirzepatide (Mounjaro)...
Browse by tag
bottom of page